Blood clotting is a complex cascade of events that works well for normal cuts and scrapes, however, more serious injuries can overwhelm the body’s natural blood-clotting process. With traumatic injury the leading cause of death for people aged 4 to 44, a team of researchers has sought a way to enhance the natural blood-clotting process by creating synthetic platelets that show promise in halting internal and external bleeding.
Blood platelets are the small, irregularly-shaped cells that circulate in the blood and are the structural and chemical foundation of blood clotting. Using other people's platelets can enhance clotting but carries risks of several complications. Plus these platelets must be refrigerated and have a short shelf life.
NEW ATLAS NEEDS YOUR SUPPORT
Upgrade to a Plus subscription today, and read the site without ads.
It's just US$19 a year.UPGRADE NOW
A team led by Erin Lavik, a new Case Western Reserve University biomedical engineering professor, and her former doctoral student, James P. Bertram, built synthetic platelets made from biodegradable polymers. The synthetic platelets are designed to home in and link up with natural platelets at the site of an injury. The natural platelets, activated by injury, emit chemicals that bind natural platelets and the additional synthetics into a larger clot that quickly stems the bleeding.
The researchers say adding their artificial platelets to an injury is akin to adding sand bags to a levy along a flooding river.
In testing, rat models injected with synthetic platelets prior to injury stopped bleeding in half the time of untreated models. Untreated models injected 20 seconds after injury stopped bleeding in 23 percent less time than models left untreated.
In another comparison, the artificial platelets resulted in clotting times about 25 percent faster than wounds treated with recombinant factor VIIa, which is the current state of the art treatment for uncontrolled bleeding in surgery and emergency rooms. While the recombinant factor is used on various injuries, its cost can be in the tens of thousands of dollars per treatment and is not used in patients suffering head or spinal cord injuries, due to risk of complications.
Lavik said her team made platelets from polymers already used in treatments approved by the Food and Drug Administration in hopes the new treatment might be approved faster. They also built the parts of the synthetic platelets that bind to natural platelets from relatively short pieces of proteins because they're more stable than longer pieces and cheaper.
To avoid formation of an artificial clot, each synthetic platelet is built with a surrounding water shield. Fluorescing compounds showed the synthetic platelets not bound in clots were flushed from the rat model's system in a day. No ill effects were seen in the following week.
Testing also showed the synthetic platelets remain viable after sitting on a shelf for at least two weeks.
The researchers were inspired by studies showing there are few options to treat soldiers suffering from internal injuries in Afghanistan and Iraq. They wanted to develop a treatment medics can keep in their field packs.
"The military has been phenomenal at developing technology to halt bleeding, but the technology has been effective only on external or compressible injuries," Lavik said. "This could be a complement to current therapies."
The researchers’ work appears in the journal Science Translational Medicine.